Table 3.
Adjusted odds ratios of adverse invasive breast cancer characteristics associated with screening interval by comorbidity and age*
| Charlson score = 0 | Charlson score ≥ 1 | |
|---|---|---|
| 2 vs 1 year | 2 vs 1 year | |
| Age group and tumor characteristics | OR (95% CI) | OR (95% CI) |
| 66–74 years | n = 1227 | n = 453 |
| Invasive (vs. DCIS) | 0.83 (0.59 to 1.17) | 0.92 (0.54 to 1.56) |
| Advanced stage (IIB-IV) | 0.75 (0.46 to 1.22) | 0.99 (0.48 to 2.04) |
| Large size (>20mm) | 0.83 (0.55 to 1.24) | 0.91 (0.50 to 1.65) |
| Positive lymph nodes | 0.84 (0.57 to 1.23) | 0.76 (0.41 to 1.43) |
| 75–89 years | n = 967 | n = 346 |
| Invasive (vs DCIS) | 1.07 (0.71 to 1.60) | 1.02 (0.51 to 2.03) |
| Advanced stage (IIB-IV) | 1.27 (0.72 to 2.25) | 0.37 (0.13 to 1.04) |
| Large size (>20mm) | 1.30 (0.83 to 2.05) | 1.38 (0.70 to 2.73) |
| Positive lymph nodes | 0.83 (0.51 to 1.33) | 0.62 (0.29 to 1.34) |
* Adjusted for the Breast Cancer Surveillance Consortium registry, age and race/ethnicity. Logistic regression analyses were used to estimate odds ratios and 95% confidence intervals of adverse (vs more favorable) tumor stage, tumor size, and nodes associated with biennial vs annual screening by comorbidity and age group. All statistical tests were two-sided. CI = confidence interval; DCIS = ductal carcinoma in situ; OR = odds ratio.